<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_y7dq9ez">Comparing Smoking Cessation Interventions among Underserved Patients Referred for Lung Cancer Screening A Pragmatic Trial Protocol</title>
				<funder ref="#_nNfz7g2">
					<orgName type="full">Patient-Centered Outcomes Research Institute</orgName>
					<orgName type="abbreviated">PCORI</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100006093</idno>
				</funder>
				<funder ref="#_R9Fdhwh">
					<orgName type="full">National Institutes of Health/National Heart, Lung, and Blood Institute</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">is Deputy Editor of AnnalsATS. His participation complies with American Thoracic Society requirements Copyright Â© 2022 by the American Thoracic Society</p>
				</availability>
				<date type="published" when="2021-05-17">May 17, 2021</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Rachel</forename><surname>Kohn</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Medicine ,</note>
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Leonard Davis Institute of Health Economics ,</note>
								<orgName type="institution">Leonard Davis Institute of Health Economics</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anil</forename><surname>Vachani</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Medicine ,</note>
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dylan</forename><surname>Small</surname></persName>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>4</label> Department of Statistics , The Wharton School , University of Pennsylvania , Philadelphia , Pennsylvania ;</note>
								<orgName type="department" key="dep1">Department of Statistics</orgName>
								<orgName type="department" key="dep2">The Wharton School</orgName>
								<orgName type="institution">University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alisa</forename><forename type="middle">J</forename><surname>Stephens-Shields</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>5</label> Department of Biostatistics , Epidemiology and Informatics ,</note>
								<orgName type="department" key="dep1">Department of Biostatistics</orgName>
								<orgName type="department" key="dep2">Epidemiology and Informatics</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dorothy</forename><surname>Sheu</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vanessa</forename><forename type="middle">L</forename><surname>Madden</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brian</forename><forename type="middle">A</forename><surname>Bayes</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marzana</forename><surname>Chowdhury</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sadie</forename><surname>Friday</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jannie</forename><surname>Kim</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">K</forename><surname>Gould</surname></persName>
							<affiliation key="aff7">
								<note type="raw_affiliation"><label>6</label> Department of Health Systems Science , Kaiser Permanente Bernard J. Tyson School of Medicine , Pasadena , California;</note>
								<orgName type="department">Department of Health Systems Science</orgName>
								<orgName type="institution">Kaiser Permanente Bernard J. Tyson School of Medicine</orgName>
								<address>
									<settlement>Pasadena</settlement>
									<region>California;</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mohamed</forename><forename type="middle">H</forename><surname>Ismail</surname></persName>
							<affiliation key="aff8">
								<note type="raw_affiliation"><label>7</label> Department of Preventive Medicine and</note>
								<orgName type="department">Department of Preventive Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Beth</forename><surname>Creekmur</surname></persName>
							<affiliation key="aff9">
								<note type="raw_affiliation"><label>8</label> Department of Research and Evaluation , Kaiser Permanente Southern California , Riverside , California;</note>
								<orgName type="department">Department of Research and Evaluation</orgName>
								<orgName type="institution">Kaiser Permanente Southern California</orgName>
								<address>
									<settlement>Riverside</settlement>
									<region>California;</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthew</forename><forename type="middle">A</forename><surname>Facktor</surname></persName>
							<affiliation key="aff10">
								<note type="raw_affiliation"><label>9</label> Department of Thoracic Surgery , Geisinger Heart Institute ,</note>
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Geisinger Heart Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Charlotte</forename><surname>Collins</surname></persName>
							<affiliation key="aff11">
								<note type="raw_affiliation"><label>10</label> Department of Psychiatry , and</note>
								<orgName type="department">Department of Psychiatry</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kristina</forename><forename type="middle">K</forename><surname>Blessing</surname></persName>
							<affiliation key="aff12">
								<note type="raw_affiliation"><label>11</label> Investigator Initiated Research Operations , Geisinger Health System , Danville , Pennsylvania ;</note>
								<orgName type="department">Investigator Initiated Research Operations</orgName>
								<orgName type="institution">Geisinger Health System</orgName>
								<address>
									<settlement>Danville</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><forename type="middle">M</forename><surname>Neslund-Dudas</surname></persName>
							<affiliation key="aff13">
								<note type="raw_affiliation"><label>12</label> Department of Public Health Sciences ,</note>
								<orgName type="department">Department of Public Health Sciences</orgName>
							</affiliation>
							<affiliation key="aff14">
								<note type="raw_affiliation"><label>13</label> Henry Ford Cancer Institute , and</note>
								<orgName type="institution">Henry Ford Cancer Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Simoff</surname></persName>
							<affiliation key="aff14">
								<note type="raw_affiliation"><label>13</label> Henry Ford Cancer Institute , and</note>
								<orgName type="institution">Henry Ford Cancer Institute</orgName>
							</affiliation>
							<affiliation key="aff15">
								<note type="raw_affiliation"><label>14</label> Department of Pulmonary and Critical Care Medicine , Henry Ford Health System , Detroit , Michigan ;</note>
								<orgName type="department">Department of Pulmonary and Critical Care Medicine</orgName>
								<orgName type="institution">Henry Ford Health System</orgName>
								<address>
									<settlement>Detroit</settlement>
									<region>Michigan</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elizabeth</forename><forename type="middle">R</forename><surname>Alleman</surname></persName>
							<affiliation key="aff13">
								<note type="raw_affiliation"><label>12</label> Department of Public Health Sciences ,</note>
								<orgName type="department">Department of Public Health Sciences</orgName>
							</affiliation>
							<affiliation key="aff14">
								<note type="raw_affiliation"><label>13</label> Henry Ford Cancer Institute , and</note>
								<orgName type="institution">Henry Ford Cancer Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Leonard</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
							<affiliation key="aff16">
								<note type="raw_affiliation"><label>15</label> Department of Pediatrics , Jacobs School of Medicine and Biomedical Sciences , University at Buffalo , Buffalo , New York ;</note>
								<orgName type="department" key="dep1">Department of Pediatrics</orgName>
								<orgName type="department" key="dep2">Jacobs School of Medicine and Biomedical Sciences</orgName>
								<orgName type="institution">University at Buffalo</orgName>
								<address>
									<settlement>Buffalo</settlement>
									<region>New York</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">A</forename><surname>Horst</surname></persName>
							<affiliation key="aff17">
								<note type="raw_affiliation"><label>16</label> Lancaster General Health Research Institute , University of Pennsylvania Health System , Lancaster , Pennsylvania ;</note>
								<orgName type="institution" key="instit1">Lancaster General Health Research Institute</orgName>
								<orgName type="institution" key="instit2">University of Pennsylvania Health System</orgName>
								<address>
									<settlement>Lancaster</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">E</forename><surname>Scott</surname></persName>
							<affiliation key="aff18">
								<note type="raw_affiliation"><label>17</label> The Center for Black Health and Equity , Durham , North Carolina ;</note>
								<orgName type="institution">The Center for Black Health and Equity</orgName>
								<address>
									<settlement>Durham</settlement>
									<region>North Carolina</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kevin</forename><forename type="middle">G</forename><surname>Volpp</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Medicine ,</note>
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Leonard Davis Institute of Health Economics ,</note>
								<orgName type="institution">Leonard Davis Institute of Health Economics</orgName>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>18</label> Department of Medical Ethics and Health Policy , and</note>
								<orgName type="department">Department of Medical Ethics and Health Policy</orgName>
							</affiliation>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>20</label> Center for Health Incentives and Behavioral Economics , Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania ;</note>
								<orgName type="department" key="dep1">Center for Health Incentives and Behavioral Economics</orgName>
								<orgName type="department" key="dep2">Perelman School of Medicine</orgName>
								<orgName type="institution">University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<note type="raw_affiliation"><label>19</label> Department of Medicine , Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia , Pennsylvania</note>
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">Corporal Michael J. Crescenz Veterans Affairs Medical Center</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Scott</forename><forename type="middle">D</forename><surname>Halpern</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Medicine ,</note>
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Leonard Davis Institute of Health Economics ,</note>
								<orgName type="institution">Leonard Davis Institute of Health Economics</orgName>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>5</label> Department of Biostatistics , Epidemiology and Informatics ,</note>
								<orgName type="department" key="dep1">Department of Biostatistics</orgName>
								<orgName type="department" key="dep2">Epidemiology and Informatics</orgName>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>18</label> Department of Medical Ethics and Health Policy , and</note>
								<orgName type="department">Department of Medical Ethics and Health Policy</orgName>
							</affiliation>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>20</label> Center for Health Incentives and Behavioral Economics , Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania ;</note>
								<orgName type="department" key="dep1">Center for Health Incentives and Behavioral Economics</orgName>
								<orgName type="department" key="dep2">Perelman School of Medicine</orgName>
								<orgName type="institution">University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joanna</forename><forename type="middle">L</forename><surname>Hart</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Palliative and Advanced Illness Research Center ,</note>
								<orgName type="department">Palliative and Advanced Illness Research Center</orgName>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Medicine ,</note>
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Leonard Davis Institute of Health Economics ,</note>
								<orgName type="institution">Leonard Davis Institute of Health Economics</orgName>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>18</label> Department of Medical Ethics and Health Policy , and</note>
								<orgName type="department">Department of Medical Ethics and Health Policy</orgName>
							</affiliation>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>20</label> Center for Health Incentives and Behavioral Economics , Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania ;</note>
								<orgName type="department" key="dep1">Center for Health Incentives and Behavioral Economics</orgName>
								<orgName type="department" key="dep2">Perelman School of Medicine</orgName>
								<orgName type="institution">University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<note type="raw_affiliation"><label>19</label> Department of Medicine , Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia , Pennsylvania</note>
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">Corporal Michael J. Crescenz Veterans Affairs Medical Center</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">L H</forename><surname>Wrote</surname></persName>
						</author>
						<author>
							<affiliation key="aff20">
								<note type="raw_affiliation">Hospital of the University of Pennsylvania , 836 Gates Building , 3400 Spruce Street , Philadelphia , PA 19104.</note>
								<orgName type="institution" key="instit1">Hospital</orgName>
								<orgName type="institution" key="instit2">University of Pennsylvania</orgName>
								<address>
									<addrLine>836 Gates Building 3400 Spruce Street</addrLine>
									<postCode>19104.</postCode>
									<settlement>Philadelphia</settlement>
									<region>PA</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_zG5RF3z">Comparing Smoking Cessation Interventions among Underserved Patients Referred for Lung Cancer Screening A Pragmatic Trial Protocol</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2021-05-17">May 17, 2021</date>
						</imprint>
					</monogr>
					<idno type="MD5">BAC1802709179AB9394507CA5E817940</idno>
					<idno type="DOI">10.1513/annalsats.202104-499sd</idno>
					<note type="submission">March 12, 2021. Received in original form April 28, 2021; accepted in final form August 12, 2021</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T06:32+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_MaMfVeS">smoking cessation</term>
					<term xml:id="_rNUsDpy">tobacco cessation</term>
					<term xml:id="_whhcuZp">vulnerable populations</term>
					<term xml:id="_hHgbvp2">pragmatic clinical trial</term>
					<term xml:id="_5WvTKtM">lung cancer screening</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_2bm2UTG"><p xml:id="_K2NvkVj"><s xml:id="_Wf2KDnX">Smoking burdens are greatest among underserved patients.</s><s xml:id="_CveSDFt">Lung cancer screening (LCS) reduces mortality among individuals at risk for smoking-associated lung cancer.</s><s xml:id="_dvFMhsf">Although LCS programs must offer smoking cessation support, the interventions that best promote cessation among underserved patients in this setting are unknown.</s><s xml:id="_CxDqmtn">This stakeholder-engaged, pragmatic randomized clinical trial will compare the effectiveness of four interventions promoting smoking cessation among underserved patients referred for LCS.</s><s xml:id="_WKSEyUv">By using an additive study design, all four arms provide standard "ask-advise-refer" care.</s><s xml:id="_26ssZkA">Arm 2 adds free or subsidized pharmacologic cessation aids, arm 3 adds financial incentives up to $600 for cessation, and arm 4 adds a mobile device-delivered episodic future thinking tool to promote attention to long-term health goals.</s><s xml:id="_mkPTD9P">We hypothesize that smoking abstinence rates will be higher with the addition of each intervention when compared with arm 1.</s><s xml:id="_2H74pad">We will enroll 3,200 adults with LCS orders at four U.S. health systems.</s><s xml:id="_FhDPeFk">Eligible patients include those who smoke at least one cigarette daily and self-identify as a member of an underserved group (i.e., is Black or Latinx, is a rural resident, completed a high school education or less, and/or has a household income ,200% of the federal poverty line).</s><s xml:id="_ASB6MDQ">The primary outcome is biochemically confirmed smoking abstinence sustained through 6 months.</s><s xml:id="_77utWBa">Secondary outcomes include abstinence sustained through 12 months, other smokingrelated clinical outcomes, and patient-reported outcomes.</s><s xml:id="_dkCmSr7">This pragmatic randomized clinical trial will identify the most effective smoking cessation strategies that LCS programs can implement to reduce smoking burdens affecting underserved populations.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="585.014" lry="782.986"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_VF6n6HQ"><p xml:id="_3ZSHeC9"><s xml:id="_qkKY7w9">Smoking remains the leading cause of preventable morbidity and mortality worldwide, causing more than 5 million deaths annually, including 500,000 in the United States <ref type="bibr" target="#b0">(1)</ref>.</s><s xml:id="_PqK2URA">The National Lung Screening Trial found that annual lung cancer screening (LCS) among patients aged 55-74 years who are current or former heavy smokers (&gt;30 pack-years) reduces mortality due to lung cancer <ref type="bibr" target="#b1">(2)</ref>.</s><s xml:id="_aKHE2MN">Thus, annual LCS became widely recommended by national guidelines and adopted by payers <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4)</ref>.</s><s xml:id="_vrVTwxw">In 2020, a U.S. Preventive Services Task Force simulated optimal screening strategies and concluded that expanding screening eligibility to patients aged 50-80 years with at least 20 pack-years of smoking history would increase the benefit and reduce existing disparities in lung cancer mortality by race, ethnicity, and sex compared with using the prior minimum age of 55 and a minimum smoking history of 30 pack-years <ref type="bibr" target="#b4">(5)</ref>.</s></p><p xml:id="_Ah7uyaE"><s xml:id="_7tzTR48">LCS provides a unique opportunity to engage the more than 5 million eligible Americans who continue to smoke tobacco <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b6">7)</ref>.</s><s xml:id="_uUEMY9M">The prevalence of smoking among individuals presenting for LCS is considerably higher than among those in the community, with 48-70% of those undergoing LCS actively smoking <ref type="bibr" target="#b7">(8)</ref>.</s><s xml:id="_FBhCXW4">Patients receiving abnormal results from their LCS stop smoking at higher rates than those with normal LCS results and those among the general population <ref type="bibr" target="#b8">(9)</ref>.</s><s xml:id="_qA7VxjQ">Those who quit smoking during the period of LCS eligibility gain an average of 4 life-years, which is more than the number of life-years gained through early lung cancer detection <ref type="bibr" target="#b9">(10)</ref>.</s><s xml:id="_2XQNGqE">Therefore, smoking cessation interventions are a required core component of LCS as per national guidelines <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b10">11)</ref> and the Centers for Medicare and Medicaid Services <ref type="bibr" target="#b11">(12)</ref>.</s></p><p xml:id="_s3MFnKV"><s xml:id="_UrUt6Hq">Embedding smoking cessation interventions within LCS programs may also mitigate the disproportionate impact of smoking on patients who are Black or Latinx, live in rural communities, and/or have a low socioeconomic status (SES) <ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref>.</s><s xml:id="_zADGmJj">These underserved populations (by which we mean historically underresourced or disenfranchised populations) <ref type="bibr" target="#b15">(16)</ref> are overrepresented among patients eligible for LCS yet are less likely to successfully quit <ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref>.</s><s xml:id="_q8j8FkB">Therefore, providing systematic smoking cessation support during LCS may begin to reduce health inequities attributable to tobacco use <ref type="bibr" target="#b19">(20,</ref><ref type="bibr" target="#b20">21)</ref>.</s></p><p xml:id="_43sSUs4"><s xml:id="_jHy4Bxg">Despite these compelling reasons to embed intensive smoking cessation services within LCS programs, numerous studies, systematic reviews, and consensus statements have noted the uncertainty regarding which interventions best promote cessation among patients undergoing LCS <ref type="bibr" target="#b3">(4,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b22">23)</ref>.</s><s xml:id="_sjycj4V">A common approach is "ask-advise-refer" (AAR), whereby patients are asked if they smoke, advised of the benefits of cessation, and referred to local cessation resources <ref type="bibr" target="#b22">(23)</ref>.</s><s xml:id="_aVbtVrz">Yet few patients achieve cessation when exposed to the AAR approach <ref type="bibr" target="#b23">(24)</ref>.</s><s xml:id="_fJ5FrDz">Because information alone is often ineffective in modifying health behaviors, interventions are needed that target specific barriers to successful smoking cessation, such as physiologic craving, the lack of an impetus to initiate the quitting process, and the human tendency to be present biased, neglecting the future health benefits resulting from cessation (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_QQAVnmn">We designed the Healthy Lungs trial to compare the effectiveness of combinations of interventions that target these barriers with the effectiveness of the AAR approach for promoting sustained smoking abstinence among underserved patients referred for LCS.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dhSAb3y">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EqFRTzw">Design and Overview</head><p xml:id="_NuMqwaM"><s xml:id="_NufNTWx">We are conducting a stakeholder-engaged, pragmatic, four-arm randomized clinical trial (RCT) among 3,200 underserved patients who smoke tobacco at the time of LCS referral.</s><s xml:id="_VRMQhtK">The trial was designed to be highly pragmatic by using the PRagmatic-Explanatory Continuum Indicator Summary 2 criteria (PRECIS-2) (Figure <ref type="figure" target="#fig_1">2</ref>; see also Table <ref type="table" target="#tab_1">E1</ref> in the online supplement) <ref type="bibr" target="#b24">(25,</ref><ref type="bibr" target="#b25">26)</ref>.</s><s xml:id="_Hb7awmP">Patients will be assigned to one of four trial arms, including one, two, three, or four smoking cessation interventions.</s><s xml:id="_bYPmMHM">All arms will provide AAR care.</s><s xml:id="_hQCN3ge">Arm 2 will add free or subsidized U.S. Food and Drug Administration (FDA)-approved pharmacologic cessation aids, arm 3 will add financial incentives to stop smoking, and arm 4 will add an episodic future thinking (EFT) tool to prompt patients to think about their future health.</s><s xml:id="_T9U3RUp">Participants will be offered enrollment in the program after LCS referral and will be randomized once their eligibility based on self-identified sociodemographic characteristics has been confirmed.</s><s xml:id="_hjGJg5g">The primary outcome is sustained, biologically confirmed smoking abstinence, requiring negative results from biochemical evaluations of nicotine metabolites at 2 weeks, 3 months, and 6 months.</s><s xml:id="_UqzwYNS">Relapse and other outcomes will be assessed at 12 months (clinicaltrials.gov</s><s xml:id="_hS7wuA8">identifier NCT 04798664; date of registration: March 12, 2021; date of trial launch: May 17, 2021) (Figure <ref type="figure">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_y2N62pb">Patient and Stakeholder Engagement</head><p xml:id="_vzg9U9B"><s xml:id="_QPJNYSY">An 11-member Stakeholder Advisory Committee (SAC) was formed to ensure that the study's aims reflect critical questions important to affected groups and that the study materials and design were appropriate for the target populations (Figure <ref type="figure" target="#fig_2">4</ref>).</s><s xml:id="_qTQa3ss">The SAC co-developed, reviewed, and revised study materials and study procedures to improve responsiveness to patient and health system needs and reduce the burden on participants.</s><s xml:id="_F4gw2e8">They reviewed the statistical analysis plan, including proposed covariates and potential confounders, for face validity and suggested secondary and sensitivity analyses.</s><s xml:id="_6NTT5CP">During the analysis stage, SAC members will identify the findings of greatest interest to patients and stakeholders and help design figures that portray the core results in understandable ways.</s><s xml:id="_wFncZEr">In addition, SAC partners will participate in manuscript preparation and result dissemination and implementation via media and internet platforms and through community organizations and health systems.</s><s xml:id="_NykdgFf">A SAC Charter was developed to help guide responsibilities, reimbursement, andcommunication expectations.</s><s xml:id="_T98R4fV">The SAC reviewed and approved the SAC Charter, research protocol, recruitment plans, and remuneration on June 14, 2019.</s><s xml:id="_CrzwCVK">Primary analysis -To what extent are all data included?</s></p><p xml:id="_tcB8S7G"><s xml:id="_r2pFuV9">Primary outcome -How relevant is it to participants?</s><s xml:id="_x8jusrT">Follow-up -How closely are participants followed-up?</s></p><p xml:id="_DJUcDKr"><s xml:id="_hG9R5H8">Flexibility -What measures are in place to make sure participants adhere to the intervention?</s></p><p xml:id="_EmMdgpK"><s xml:id="_wNThrP2">Flexibility -How should the intervention be delivered?</s></p><p xml:id="_FtkqUrQ"><s xml:id="_KTFQ8Xg">Organization -What expertise and resources are needed to deliver the intervention?</s></p><p xml:id="_VRjEhjG"><s xml:id="_S3dZNRs">Setting -Where is the trial being done?</s></p><p xml:id="_StjY3Nq"><s xml:id="_NAVmBnk">Recruitment -How are participants recruited into the trial?</s></p><formula xml:id="formula_0">1 2 3 4<label>5</label></formula><p xml:id="_Jb9qSHr"><s xml:id="_K5wWvYW">Eligibility -Who is selected to participate in the trial?</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_tkTCkwG">CLINICAL STUDY DESIGN</head><p xml:id="_7npksYP"><s xml:id="_eCRMqkJ">Clinician/patient shared-decision making conversation Lung cancer screening (LCS) order Post-order email and/or text: patient registration request Patient registers on study platform before or during LCS shared decision-making or low-dose computed tomography (CT) visit Screening questions Ineligible Opt-out consent Self-report quit?</s><s xml:id="_Rmmmym4">If so, sample submission Patient reported outcomes (PRO) survey Payment for PRO completion or sample submission Cessation-dependent incentive payment ARM 1 Ask-Advise-Refer ARM 2 Ask-Advise-Refer Free/Subsidized Pharmacotherapy Target quit date set within 60 days 2 weeks 3 months 6 months 12 months ARM 3 Ask-Advise-Refer Free/Subsidized Pharmacotherapy Financial incentives ARM 4 Ask-Advise-Refer Free/Subsidized Pharmacotherapy Financial Incentives Episodic Future Thinking Patient-level randomization Yes Outreach to unregistered patients No Figure 3. Study schema.</s><s xml:id="_Pc3MQjA">CT = computed tomography; LCS = lung cancer screening; PRO = patient-reported outcomes.</s><s xml:id="_e4SNfnG">CLINICAL STUDY DESIGN 306 AnnalsATS Volume 19 Number 2 | February 2022 Study Setting We are testing the interventions among patients referred for LCS at the University of Pennsylvania Health System (Penn), Geisinger Health System (Geisinger), Henry Ford Health System (Henry Ford), and Kaiser Permanente Southern California (KPSC).</s><s xml:id="_2CjGeSm">We selected these sites because each serves a core constituent of our underserved patient groups.</s><s xml:id="_D3buvHV">Penn serves the Philadelphia Metro area, nearly half of Penn's patients are Black, and many of Penn's patients have a low SES (nearly 70% have a high school degree or less; over 25% live below the federal poverty line [FPL]).</s><s xml:id="_fmWZzby">Lancaster General Health (LGH), a part of Penn, serves patients from both low-SES urban and low-SES rural residences in Pennsylvania (approximately 75% have a high school degree or less; approximately 30% live below the FPL), including a .35%</s><s xml:id="_MxrrfYe">Latinx population.</s><s xml:id="_yhtVzAW">Geisinger serves patients who are predominantly white (.90%) from rural residences in Pennsylvania, and more than half have a low SES (65% have a high school degree or less; approximately 15% live below the FPL).</s><s xml:id="_vqbkQYf">Henry Ford serves patients in the Detroit Metro area, .20% of their patients are Black, and approximately 70% have a low SES (.60% have a high school degree or less; approximately 40% live below the FPL).</s></p><p xml:id="_RtjekK3"><s xml:id="_wmm8JJk">KPSC is an integrated health system that serves a population that is approximately 40% Latinx and also includes those who have a low SES (.60% have a high school degree or less; approximately 40% live below the FPL) <ref type="bibr" target="#b26">(27)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MSPVDhC">Population</head><p xml:id="_wUJFcNB"><s xml:id="_saDFNDG">We aim to enroll 3,200 adult patients who have had an LCS order placed in the electronic health record by any clinician, smoke at least one cigarette daily (not including e-cigarettes) at the time of study eligibility screening, have access to a phone with text messaging, and are underserved, defined as having one or more of the following characteristics: Black or Latinx race or ethnicity; rural community residence based on self-report or, in the absence of selfreported data, residence within an area with a Rural-Urban Commuting Area code of .1 as determined by using the ZIP code; completion of a high school education or less; and/or a household income ,200% of the FPL.</s><s xml:id="_qYnBmAW">For the first 2 months of the trial, we required that patients smoke at least five cigarettes per day to be eligible, consistent with our prior trials <ref type="bibr" target="#b27">(28,</ref><ref type="bibr" target="#b28">29)</ref>.</s><s xml:id="_bBzUjph">However, in light of more recent evidence that a quarter of Americans who smoke do so lightly <ref type="bibr" target="#b29">(30)</ref>, the recognition of the financial barriers to heavier smoking in our target sample, and the unanimous recommendation of our SAC, we have since modified the criterion to one cigarette per day or more.</s></p><p xml:id="_bhCxGdu"><s xml:id="_mbmdx9k">All study-related activities will rely on a web-based platform, text messaging, and intermittent internet access for participation.</s><s xml:id="_HaUhQ3Y">To facilitate participation and inclusivity, our SAC community partners prepared comprehensive lists of locations with free internet access throughout each health system catchment, which will be provided to participants.</s><s xml:id="_KhkysBy">For full program participation, patients will be required to participate in a minimum of six web-based activities over a 12-month study period (registration on study platform/eligibility screening/randomization/ baseline survey; setting a target quit date [TQD]; and short assessments at 2 wk, 3 mo, 6 mo, and 12 mo) (Figure <ref type="figure">3</ref>).</s><s xml:id="_aW6WgjV">All studyrelated activities will be offered in English and Spanish; patients fluent in neither language will be excluded.</s><s xml:id="_Xrz5HFR">We anticipate that LCS orders will reflect national screening guidelines, but we will not exclude any adult patients for whom clinicians have ordered LCS <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b30">31)</ref>.</s><s xml:id="_RhAy3EW">Patients will receive all studyrelated payments through reloadable prepaid cards that can be used as debit cards or redeemed for cash at any bank (Figure <ref type="figure">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_A3T6xDB">Interventions</head><p xml:id="_UaPCptn"><s xml:id="_FjCAc4S">Patients will be randomized to one of four study arms.</s><s xml:id="_aDM46qZ">Each arm is additive and contains the interventions from the prior arm.</s><s xml:id="_4AY5NAu">All randomized patients will be asked to set a TQD within 60 days of enrollment, which was decided on the basis of SAC feedback.</s><s xml:id="_cMwBb6D">If no TQD is selected, a default TQD will be set to 60 days after enrollment.</s><s xml:id="_DqW89fE">All study-related activities will be based on each patient's TQD (Figure <ref type="figure">3</ref>).</s></p><p xml:id="_6UzP4EB"><s xml:id="_W2xtuZu">Arm 1: AAR.</s><s xml:id="_sDzwZ6g">AAR is a minimum standard to promote smoking cessation during LCS <ref type="bibr" target="#b31">(32)</ref>.</s><s xml:id="_yuUka5P">Clinicians may ask patients whether they smoke, advise them regarding the benefits of cessation if they are actively using tobacco, and refer patients who are using tobacco to local or national resources.</s></p><p xml:id="_fvJJbqb"><s xml:id="_MzVJyKv">After enrollment, we will offer all patients information through the patient portal that includes national quit hotlines and local health system resources (e.g., smoking cessation clinics) they may choose to pursue.</s><s xml:id="_rKUTxwS">We will advise patients to speak with their clinician about these and other available resources.</s><s xml:id="_7JqzjR6">We will inform them that they will be sent text messages and/or e-mails on their TQD and at 2 weeks, 3 months, and 6 months to assess their smoking cessation status.</s><s xml:id="_TdHBkX6">Because usual care at KPSC includes no-cost provision of smoking cessation pharmacotherapy for all patients, no KPSC patients will be randomized to arm 1.</s></p><p xml:id="_vdnRVUm"><s xml:id="_stpYZwr">Arm 2: FDA-approved pharmacotherapy.</s><s xml:id="_Fy2gwMR">Pharmacotherapy (e.g., nicotine replacement therapy [NRT], varenicline, and bupropion) can reduce nicotine withdrawal symptoms and decrease tobacco cravings.</s><s xml:id="_M77TCSv">NRT is direct nicotine replacement.</s><s xml:id="_SPTTKEB">Varenicline is a partial neuronal a 4 b 2 nicotinic receptor agonist, which prevents nicotine stimulation of the mesolimbic dopamine system associated with nicotine addiction.</s><s xml:id="_AUrbM9R">Bupropion is believed to enhance central nervous system noradrenergic and dopaminergic release <ref type="bibr" target="#b32">(33)</ref><ref type="bibr" target="#b33">(34)</ref><ref type="bibr" target="#b34">(35)</ref>.</s><s xml:id="_ZTgRgxV">NRT, varenicline, and bupropion all improve smoking cessation rates compared with placebo and are recommended as firstline therapies for tobacco dependence <ref type="bibr" target="#b35">(36)</ref>.</s><s xml:id="_cyukt9w">We do not offer e-cigarettes as part of this trial because they are not FDA-approved for smoking cessation.</s></p><p xml:id="_fw8BuuY"><s xml:id="_bbCJt6T">Some insurers (e.g., KPSC) have already adopted Affordable Care Act guidance to cover all copays associated with smoking cessation aids for most of their members <ref type="bibr" target="#b36">(37)</ref>.</s><s xml:id="_4xKmAak">However, many underserved patients do not receive such coverage <ref type="bibr" target="#b37">(38,</ref><ref type="bibr" target="#b38">39)</ref>.</s><s xml:id="_m8ECuRW">Patients assigned to arms 2-4 may order NRT (i.e., patches, lozenges, or gum) directly from their patient portal at no cost for mail delivery, as in our recent trial, because these are available without prescriptions <ref type="bibr" target="#b28">(29)</ref>.</s><s xml:id="_Mrs65vM">Because of vendor limitations, some forms of NRT are not available (i.e., nasal sprays and oral inhalers).</s><s xml:id="_qrmENSF">Patients who receive prescriptions from their clinicians for varenicline or bupropion will submit receipts through the patient portal for co-payment or out-of-pocket reimbursements up to $300 total.</s><s xml:id="_MyByrM3">Educational materials about optimal pharmacotherapy use, co-developed with the SAC, will be available in the portal and will be mailed in a participant welcome packet.</s></p><p xml:id="_y4X4Aee"><s xml:id="_nvvKBVH">Arm 3: financial incentives.</s><s xml:id="_dMsbUDU">Patients will be eligible to earn $100, $200, and $300 if they submit negative test results for nicotine metabolites at 2 weeks, 3 months, and 6 months after their TQD, respectively (Table <ref type="table" target="#tab_2">E2</ref>).</s><s xml:id="_Q9SCG2S">These are the identical financial incentives and schedule that have been shown to triple quit rates among similarly nonselected people who smoke who also</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_F73ktVa">CLINICAL STUDY DESIGN</head><p xml:id="_dxyzvGg"><s xml:id="_uSnAdjA">have access to free cessation aids <ref type="bibr" target="#b28">(29)</ref>, and these incentives and this schedule have recently been demonstrated to be highly cost-effective from a societal perspective <ref type="bibr" target="#b39">(40)</ref>.</s><s xml:id="_qm6FzU6">This strategy is based in behavioral economic theory, including 1) providing substitute, proximal reinforcers of cessation in the form of incentives (41); 2) using large payments to reinforce target behaviors <ref type="bibr" target="#b41">(42)</ref>; and 3) providing the largest payment at the end of the intervention to offset the present bias of patients who smoke <ref type="bibr" target="#b42">(43)</ref>.</s></p><p xml:id="_UCPHeDr"><s xml:id="_qa4gsHD">Arm 4: EFT.</s><s xml:id="_wdb8ADe">Patients who smoke tend to be "present biased" with a propensity to discount future benefits (e.g., greater health after smoking cessation) in favor of immediate satisfaction (e.g., the pleasures of smoking and avoidance of the discomfort of nicotine withdrawal) <ref type="bibr" target="#b43">(44,</ref><ref type="bibr" target="#b44">45)</ref>.</s><s xml:id="_bh3Wmp7">By contrast, cancer screening is an event that naturally motivates people to adopt a future orientation <ref type="bibr" target="#b43">(44,</ref><ref type="bibr" target="#b45">46)</ref> as they contemplate how their future health may be affected by tobacco use <ref type="bibr" target="#b19">(20,</ref><ref type="bibr" target="#b46">47)</ref>.</s><s xml:id="_JjVvGSC">EFT as an intervention is an evidencebased, personalized behavioral tool that promotes prospective thinking about longerterm rewards <ref type="bibr" target="#b47">(48)</ref>.</s><s xml:id="_pZEnAMk">EFT interventions have been used successfully to promote behavior change in a variety of contexts, such as obesity, alcohol use disorder, and tobacco dependence <ref type="bibr" target="#b48">(49)</ref><ref type="bibr" target="#b49">(50)</ref><ref type="bibr" target="#b50">(51)</ref>.</s><s xml:id="_Gd25dDp">EFT prompts individuals to engage in thinking about delayed rewards (e.g., the benefits of smoking cessation) to overcome a focus on immediate rewards (e.g., the relief from a nicotine craving) through two mechanisms: the process of generating personalized future positive event "cues" about positive future experiences (see the online supplement for a sample cue) and then the delivery of these personalized cues by text message at regular intervals and on demand to promote future orientation as needed (e.g., when craving cigarettes) <ref type="bibr" target="#b48">(49)</ref><ref type="bibr" target="#b49">(50)</ref><ref type="bibr" target="#b50">(51)</ref>.</s><s xml:id="_vDZ3K8P">EFT may work in a complementary fashion with financial incentives, with incentives providing an immediate, extrinsic motivation to quit and EFT helping to sustain abstinence by enhancing people's intrinsic motivations to quit.</s><s xml:id="_BG6g7mx">EFT has previously proven effective among patients living in poverty <ref type="bibr" target="#b51">(52)</ref>.</s></p><p xml:id="_DxrgVJj"><s xml:id="_zKtQWkW">Patients will be able to view introductory videos, co-developed and narrated by SAC members, on the study platform to orient them to personalizing and using the EFT tool (see the online supplement for links to the participant-facing explanatory videos designed for the study).</s><s xml:id="_KQ6v48H">This information will also be provided in the mailed participant welcome packet.</s><s xml:id="_nQpRXYq">When first engaging with EFT, patients will generate three EFT cues that are positive, specific, vivid descriptions of events that they are looking forward to and that are enhanced by smoking cessation.</s><s xml:id="_mWP9bKr">Over the 6-month intervention period, the mobile study platform will regularly prompt patients to focus on delayed rewards from smoking cessation through scheduled and on-demand text messages with their personalized EFT cues.</s><s xml:id="_Zm6tqF2">Patients may update their cues at any time during the study period.</s><s xml:id="_48JgZB9">Patients will receive cues from the TQD through the end of the intervention period unless they ask to stop receiving cues sooner.</s><s xml:id="_zY4zKXR">Patients who create three cues will be paid $20 and classified as having engaged with the intervention for the purposes of analysis (Table <ref type="table" target="#tab_2">E2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EUTAuQk">Recruitment</head><p xml:id="_NTPHeX7"><s xml:id="_RHYv3zk">Recruitment began in May of 2021 at Penn, and a staggered roll-out across Penn radiology clinics was used to enable quality assessments of all study-related procedures.</s></p><p xml:id="_QF7G7hP"><s xml:id="_9ws5nv6">Recruitment will begin at the other health systems in serial fashion over the ensuing 4 months.</s><s xml:id="_RNN72Td">On the basis of annual screening volumes from each health system and estimates of the proportions of screened patients who will be eligible, we anticipate that recruitment will continue for 32 months to enroll the target of 3,200 patients.</s><s xml:id="_yvCHRrQ">Consistent with the goals of a large, scalable, pragmatic RCT to assess the real-world effectiveness of interventions, recruitment will occur via a three-pronged approach that will not rely on on-site research personnel (Table <ref type="table">E3</ref>).</s><s xml:id="_QFgAVzu">Patients will receive financial remuneration for study-related tasks and will be sent up to five reminder text message and/ or e-mail reminders at each study milestone to promote retention.</s><s xml:id="_mcxgxnS">Because of the pragmatic nature of this trial, retention efforts delivered outside of automated means are incompatible with the goals of this study.</s><s xml:id="_q5QFsPR">Patients recruited after shared decisionmaking visits who were referred to cessation resources or prescribed cessation pharmacotherapy remain eligible for study participation.</s><s xml:id="_75gPETQ">Patients who have an LCS referral or order but do not schedule an appointment within 120 days will also be contacted for study enrollment via a text message, e-mail, and/or letter.</s><s xml:id="_BxnbvEp">There is a centralized study telephone hotline staffed with English-and Spanish-speaking research staff to answer questions and assist in enrollment and study participation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HKaRkYV">Patient partners representing:</head><p xml:id="_McuZQhS"><s xml:id="_aw9gDkE">x Those who formerly smoked tobacco (n=2)</s></p><p xml:id="_HNd6hhj"><s xml:id="_Sgjfdgk">x Smoking-associated diseases like COPD (n=1)</s></p><p xml:id="_P92dJcm"><s xml:id="_TjwjfjE">Stakeholder partners, including:</s></p><p xml:id="_qNQAGj9"><s xml:id="_5UHjmJC">x Healthcare executive and payer leadership from two integrated health systems (n=2) x Clinician and program management leadership within two large health system-run smoking cessation clinics (n=2) Geographical coverage in:</s></p><p xml:id="_MUYjnYf"><s xml:id="_4brAwMw">x 5 states, including PA, NC, IL, CA, and MI (n=11) x Rural and urban communities (n=11) Community, policy, and advocacy leadership from:</s></p><p xml:id="_FeSZAWJ"><s xml:id="_evaGQvv">x A local government tobacco policy program (n=1) x A lung cancer foundation (n=1) x A tobacco prevention network and civil rights organization (n=1) x A community organization leader focused on Black health, wellness, and opportunity (n=1) x A Latino health communications agency (n=1)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WWEyXNt">CLINICAL STUDY DESIGN</head><p xml:id="_shG7wPy"><s xml:id="_FeB5tNE">Eligible patients may opt out of study participation after reviewing study-related materials, including an optional review of a detailed frequently-asked-questions document describing all elements of the trial <ref type="bibr" target="#b28">(29,</ref><ref type="bibr" target="#b52">53)</ref>.</s><s xml:id="_5AeRpEW">Such opt-out consent is advocated for in pragmatic RCTs that are testing methods for improving the delivery of interventions within health systems <ref type="bibr" target="#b53">(54,</ref><ref type="bibr" target="#b54">55)</ref>.</s><s xml:id="_TJsxFEe">Our SAC co-developed the approach to optout consent for this study, and our prior work has demonstrated that it is acceptable to underserved patients <ref type="bibr" target="#b55">(56,</ref><ref type="bibr" target="#b56">57)</ref>.</s><s xml:id="_JQw7Bzd">Details of the study arms will not be disclosed to potential study participants to avoid feelings of resentment or deprivation due to arm assignment <ref type="bibr" target="#b28">(29,</ref><ref type="bibr" target="#b57">58)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9g6qVZX">Patient Remuneration for Studyrelated Tasks</head><p xml:id="_bPt8EeW"><s xml:id="_vZ6Wayj">The 12-month maximal remuneration schedule for surveys, biochemical samples, and financial incentives is shown in Table <ref type="table" target="#tab_2">E2</ref>.</s><s xml:id="_BtaBYwp">All enrolled patients will be asked to complete 6-and 12-month surveys, regardless of their self-reported smoking abstinence, and will be compensated $40 for each.</s><s xml:id="_Xvuq949">At the 2-week and 3-, 6-, and 12-month time points, patients will report whether they are actively smoking and will be compensated $5 for completing this short assessment.</s><s xml:id="_w6m4J6b">Patients who self-report abstinence will be paid $45 for submitting a sample at an outpatient laboratory or $15 for submitting a sample by using a mobile service that collects samples at home through 6 months; these payments will be increased to $95 and $35, respectively, at 12 months to promote long-term retention.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mgRHqGb">Randomization</head><p xml:id="_WfKPZwE"><s xml:id="_BqHMEx5">Patients will be randomized individually to one of the four study arms by using random number generation within the mobile study platform, stratified by health system.</s><s xml:id="_NSHnZ5d">At Penn, Geisinger, and Henry Ford, patients will be assigned equally to each of the four arms.</s><s xml:id="_S2P9EVN">Although LGH is part of Penn, randomization will occur separately because LGH has a separate LCS program and a separate electronic health record system.</s><s xml:id="_Z57cux9">Patients enrolled at KPSC will only be assigned to arms 2-4, each with a 33% probability, as KPSC provides smoking cessation aids to all patients at no additional cost, making arm 2 the KPSC minimum standard of care, as no patients will receive AAR (arm 1) alone.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_weGcmZb">Outcomes</head><p xml:id="_CCYzeAQ"><s xml:id="_aKSsEzx">Our primary outcome is sustained abstinence for 6 months, requiring selfreported smoking cessation followed by biochemical confirmation at 2 weeks, 3 months, and 6 months (Table <ref type="table">E4</ref>), as supported by professional societies and stakeholders, including our SAC, and used in our prior RCTs <ref type="bibr" target="#b3">(4,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b58">59)</ref>.</s><s xml:id="_BmJ6ZJK">To allow for a recommended grace period after the TQD <ref type="bibr" target="#b59">(60)</ref>, all patients will be allowed a "second chance" if they do not demonstrate abstinence at 2 weeks.</s><s xml:id="_GKEJFfK">From that date, patients will be given an additional 2 weeks to quit and demonstrate abstinence.</s><s xml:id="_8qYe8f4">Patients who do not complete study-related tasks, including survey completion and confirmatory biochemical specimen submission, will be classified as not having sustained abstinence <ref type="bibr" target="#b27">(28,</ref><ref type="bibr" target="#b28">29)</ref>.</s></p><p xml:id="_gfATGUd"><s xml:id="_hQgFRns">Secondary outcomes, co-developed with the SAC, include point-prevalent biochemically confirmed quit rates at 2 weeks, 3 months, and 12 months; pointprevalent self-reported quit rates at 2 weeks, 3 months, 6 months, and 12 months; pointprevalent self-reported other tobacco use at 2 weeks, 3 months, 6 months, and 12 months; and patient-reported outcomes, including motivation to quit <ref type="bibr" target="#b60">(61)</ref>, self-efficacy to quit smoking <ref type="bibr" target="#b61">(62)</ref>, perceived barriers to cessation <ref type="bibr" target="#b62">(63)</ref>, temporal discounting <ref type="bibr" target="#b63">(64)</ref>, and healthrelated quality of life (65) (Table <ref type="table" target="#tab_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dDF4eaZ">Analytic Plan</head><p xml:id="_KpP93Pa"><s xml:id="_wBp4PjN">Sample size and power.</s><s xml:id="_gdWYMQB">On the basis of our previous trials and the target population, we anticipate a 6-month smoking abstinence rate of 2.5% with AAR (arm 1).</s><s xml:id="_ajt9NXz">Although higher rates were observed in the National Lung Screening Trial usual-care arm <ref type="bibr" target="#b9">(10)</ref>, that trial used self-reporting to determine</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Mye7BKM">CLINICAL STUDY DESIGN</head><p xml:id="_8za9fV9"><s xml:id="_CRteuxB">smoking status and enrolled motivated patients, in contrast to the unselected population to be enrolled in this pragmatic trial.</s><s xml:id="_aGhsV4b">For example, patients may enroll in the trial who are not interested in cessation (e.g., they may not select a TQD, and a default TQD will be assigned to them).</s><s xml:id="_hzDDV7q">On the other hand, the rate of 2.5% is higher than the 1% observed in the usual-care arm of our prior pragmatic trial of smoking cessation <ref type="bibr" target="#b28">(29)</ref>, accounting for the greater propensity of patients undergoing LCS to quit.</s><s xml:id="_aAHuDcw">We wish to detect absolute differences of &gt;5% in smoking abstinence rates between arm 1 and any arm among arms 2-4 or between any two arms among arms 2-4 (six total contrasts).</s><s xml:id="_qafbB4T">This difference is clinically important, given the dramatic health benefits of smoking cessation and the low rates of success of available interventions, and is identical to that used to determine power in our recent pragmatic RCTs <ref type="bibr" target="#b27">(28,</ref><ref type="bibr" target="#b28">29)</ref>.</s><s xml:id="_UJCC5j8">We project enrollment of 470 patients in arm 1 and 910 patients per arm in arms 2-4 (as no patients from KPSC will be randomized to arm 1), for a total of 3,200 patients.</s><s xml:id="_4JqfkDz">This sample and distribution will yield .80% power to detect a difference of 5% in each of the six contrasts of interest while using the Proschan method of comparing arms 2-4 with arm 1 by using a P value of 0.05 divided by 3 and comparing arms 2-4 with one another by using a P value of 0.05 divided by 3, preserving the familywise type I error rate of 5% (66).</s><s xml:id="_pWAcMgp">We will classify patients lost to follow-up as having continued smoking.</s><s xml:id="_JYcBkg4">Primary analyses.</s><s xml:id="_nf27nNh">We will use intention-to-treat analyses incorporating a generalized linear model with a logit link function to estimate the effect of each arm among arms 2-4 as compared with the effect of arm 1 to compare the overall effectiveness of the interventions in achieving sustained smoking abstinence among all randomized patients at 6 months.</s><s xml:id="_FCUc62A">Analyses will include the prespecified baseline covariates <ref type="bibr" target="#b66">(67)</ref>, including age, sex, race, ethnicity, education, income, self-reported rurality or Rural-Urban Commuting Area code, the burden of chronic comorbid conditions, temporal discounting, the degree of nicotine dependence <ref type="bibr" target="#b67">(68)</ref>, the number of prior LCSs, and LCS results.</s><s xml:id="_97hv25s">We include the number of prior LCSs and LCS results because LCS has been demonstrated to be a "teachable moment," and concerning results may further increase patients' engagement with or interest in smoking cessation <ref type="bibr" target="#b19">(20,</ref><ref type="bibr" target="#b68">69)</ref>.</s><s xml:id="_BbacbYC">Analyses will also include fixed-effect terms for the health system, preventing confounding by system and adjusting variance estimates to account for potential similarities among patients within a given system.</s></p><p xml:id="_eCdgU5P"><s xml:id="_2SCGxuQ">Secondary analyses.</s><s xml:id="_ZzyxyzD">We will perform similar analyses for sustained smoking abstinence at 12 months.</s><s xml:id="_wrcDrSs">We will use logistic and Poisson models to assess the pointprevalent and patient-reported secondary outcomes at the specified time points.</s></p><p xml:id="_K8rbfR9"><s xml:id="_murGewc">To test for heterogeneity of treatment effects, we will include terms for statistical interactions between a priori-selected patient characteristics (Table <ref type="table">E5</ref>) and the contrast of each study arm in the foregoing primary analytic model.</s><s xml:id="_rk3AUBN">In addition, because the intention-to-treat approach will yield effect sizes that are influenced by the fact that some randomized patients will not use the interventions offered to them, we will compare interventions' complier average causal effects (CACEs) by using a two-stage residual inclusion model <ref type="bibr" target="#b69">(70)</ref> in which the randomization arm is used as an instrumental variable <ref type="bibr" target="#b70">(71,</ref><ref type="bibr" target="#b71">72)</ref>.</s><s xml:id="_A4Z55gQ">Unlike perprotocol analyses, CACE analyses use data on all randomized patients to provide unbiased estimates of the effects of using the interventions, after accounting for differences in uptake rates across arms.</s></p><p xml:id="_v7AQ9sV"><s xml:id="_2mBBA9k">Finally, we will conduct sensitivity analyses of the primary contrasts that include health system fixed effects but not patientlevel covariates.</s><s xml:id="_GJaTJNj">We will follow all CONSORT (Consolidated Standards of Reporting Trials) reporting guidelines <ref type="bibr" target="#b72">(73)</ref>.</s><s xml:id="_cAK2cHX">Statisticians blinded to the trial arm will prepare reports describing all data by using appropriate summary statistics with estimates of variance and graphic representations of the distributions.</s><s xml:id="_qW2EDvK">We will compare distributions of the characteristics of enrolled patients with those of all patients identified as potentially eligible to quantify the trial's external validity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yz2DxQg">Ethics</head><p xml:id="_5mvvMq6"><s xml:id="_s2nGp6g">Regulation.</s><s xml:id="_ChNN3XD">The trial has been approved by the Penn Institutional Review Board (IRB), which serves as the single IRB for the study, including the alteration to the informedconsent requirement <ref type="bibr" target="#b73">(74)</ref>.</s></p><p xml:id="_6GHBDwc"><s xml:id="_3VcEF5y">Data Safety and Monitoring Board.</s><s xml:id="_vd3zGdC">To guide the safe and ethical conduct of this study, we assembled a Data Safety and Monitoring Board (DSMB).</s><s xml:id="_X9KudBs">The DSMB consists of five individuals with relevant expertise who reviewed and approved the DSMB Charter, statistical analysis plan, research protocol, and plans for ongoing data and safety monitoring before the start of recruitment.</s><s xml:id="_m6vaheN">The DSMB will evaluate patient risk versus benefit; make recommendations to ensure identified issues are appropriately addressed; and make recommendations about study progress, safety, or trial continuation on the basis of the futility of patient accrual.</s><s xml:id="_uFJCwd3">We have no prespecified adverse or serious adverse events that will be monitored during the study.</s><s xml:id="_h7EeQPg">All patient-, family-, and clinicianreported concerns arising during the study will be reported to the IRB and DSMB.</s><s xml:id="_szXNNvm">The SAC also advised on the study design, including the informed-consent processes, compensation, and risk communication among underserved groups.</s><s xml:id="_6sS8evX">For potential risks to trial patients, see the online supplement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PceVxa3">Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dhn9jwx">Comparison with Other Trials</head><p xml:id="_rw6Z29D"><s xml:id="_SXrAge3">This trial will add novel knowledge to the findings of prior studies assessing smoking cessation interventions in the context of LCS.</s><s xml:id="_TdkyWZG">The largest smoking cessation intervention collaboration to date is the SCALE (Smoking Cessation within the Context of LCS) Collaboration.</s><s xml:id="_DQZ35vb">We aim to enroll a larger sample of participants than has been used in prior similar trials (3,200 patients vs. 1,650 patients in the largest SCALE trial).</s><s xml:id="_xcRwsfA">Our trial is the first using a pragmatic RCT study design to exclusively enroll underserved patients (100% underserved patients vs. 37% Black patients and 33% Latinx patients as the largest underserved populations in SCALE trials) for whom LCS has been ordered.</s><s xml:id="_tp48Urr">Healthy Lungs is also the first study to incorporate additive interventions, including those demonstrated to promote smoking cessation among underserved populations, into smoking cessation trials within the context of LCS (Table <ref type="table" target="#tab_2">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WBc7vE7">Limitations of the Present Study</head><p xml:id="_x8tfRRW"><s xml:id="_HCVrXcd">This highly pragmatic trial has certain limitations.</s><s xml:id="_5FkYs85">First, a fundamental challenge of pragmatic trials is designing a flexible yet effective intervention adherence plan to enhance fidelity.</s><s xml:id="_zgsR8Nu">Although co-investigators and SAC members have collaborated to develop methods that optimize uptake and use of the interventions, including a systematic approach of multifaceted patient reminders and compensation to encourage timely completion of surveys and CLINICAL STUDY DESIGN biochemical sample collection, some participants will not engage in the offered interventions.</s><s xml:id="_skusUuE">However, the secondary CACE analysis will provide unbiased estimates of the specific efficacy of using the interventions among all patients who would use the interventions if assigned to receive them.</s><s xml:id="_PuUGRuE">Second, the underserved populations we seek to enroll may lack access to text message-capable phones or reliable internet access.</s><s xml:id="_GFGSNfH">Although our study relies on a webbased platform and text messaging for participation, we worked with the SAC to design the study to require only text message capabilities (i.e., rather than smartphone access) and intermittent internet access.</s><s xml:id="_QZs5YMR">To facilitate participation, our SAC community partners prepared comprehensive lists of locations with free internet access throughout each health system catchment, which will be provided to participants.</s><s xml:id="_HG8XQu6">In addition, over 95% of Americans have been shown to have a cellphone, with 85% having a smartphone <ref type="bibr" target="#b74">(75)</ref>.</s><s xml:id="_yQTmP99">Third, patients who have primary languages other than English and Spanish will not be represented in our study.</s><s xml:id="_sUm8vPt">However, 92% of the U.S. population is fluent in English or Spanish (76).</s><s xml:id="_TzQdCk2">Fourth, this study does not seek to increase LCS, which is underutilized <ref type="bibr" target="#b76">(77)</ref>.</s><s xml:id="_WmD5bJb">Finally, we chose to use urine anabasine for a smoking abstinence biochemical confirmatory test for patients reporting NRT use rather than serum carboxyhemoglobin for participant ease and retention.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_AUpNZYg">Potential Outcomes and Conclusions</head><p xml:id="_48t5c6r"><s xml:id="_WYZYPWx">The interventions being tested in this trial represent the first application of smoking</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FFigure 1 .</head><label>1</label><figDesc><div><p xml:id="_VYE5GKb"><s xml:id="_f6AAMpe">Figure 1.</s><s xml:id="_ttHKa28">Conceptual model.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p xml:id="_qUqaA9y"><s xml:id="_N3NQqAf">Figure 2. Pragmatism of the proposed trial based on PRagmatic-Explanatory Continuum Indicator Summary 2 criteria (PRECIS-2) (25, 26).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 4 .</head><label>4</label><figDesc><div><p xml:id="_rxksScm"><s xml:id="_jvB6QEN">Figure 4. Stakeholder Advisory Committee members.</s><s xml:id="_Kskkqmw">COPD = chronic obstructive pulmonary disease.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_x552ncS"><s xml:id="_7n2JXzN">Secondary patient-reported outcomes</s></p></div></figDesc><table><row><cell>Patient-reported Outcome</cell><cell>Measure</cell><cell>Description</cell></row><row><cell>Motivation to quit</cell><cell>Stages of change (78)</cell><cell>Validated 1-item measure to assess a</cell></row><row><cell></cell><cell></cell><cell>patient's self-reported motivation to quit</cell></row><row><cell>Self-efficacy to quit smoking</cell><cell>Situational measure of self-efficacy (62, 79)</cell><cell>Validated 10-item measure to assess how</cell></row><row><cell></cell><cell></cell><cell>certain a patient is that they can avoid</cell></row><row><cell></cell><cell></cell><cell>smoking under various situational</cell></row><row><cell></cell><cell></cell><cell>circumstances</cell></row><row><cell>Perceived barriers to cessation</cell><cell>Challenges to stopping smoking scale (63)</cell><cell>Validated 21-item measure to assess a</cell></row><row><cell></cell><cell></cell><cell>patient's perceived barriers to smoking</cell></row><row><cell></cell><cell></cell><cell>cessation. It contains two subscales:</cell></row><row><cell></cell><cell></cell><cell>intrinsic factors (physical, psychologic, or</cell></row><row><cell></cell><cell></cell><cell>cognitive aspects of quitting) and</cell></row><row><cell></cell><cell></cell><cell>extrinsic factors (social or environmental</cell></row><row><cell></cell><cell></cell><cell>aspects of quitting)</cell></row><row><cell>Temporal discounting</cell><cell>Five-trial adjusting delay task (64)</cell><cell>Validated 5-item measure to assess a</cell></row><row><cell></cell><cell></cell><cell>patient's temporal discounting toward</cell></row><row><cell></cell><cell></cell><cell>delayed rewards</cell></row><row><cell>Health-related quality of life</cell><cell>EuroQol-5 dimensions (80)</cell><cell>Validated 25-item measure used to assess</cell></row><row><cell></cell><cell></cell><cell>a patient's perceived health-related</cell></row><row><cell></cell><cell></cell><cell>quality of life across the domains of</cell></row><row><cell></cell><cell></cell><cell>mobility, self-care, usual activities, pain/</cell></row><row><cell></cell><cell></cell><cell>discomfort, and anxiety/depression</cell></row></table><note xml:id="_GQCGh84"><p><s xml:id="_vEqPApQ">Definition of abbreviation: EuroQol = European Quality of Life Scale.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s xml:id="_3EUKWwk">Comparison of Healthy Lungs (present study) with the SCALE Collaboration trialsDefinition of abbreviations: AAR = ask-advise-refer; RCT = randomized clinical trial; SCALE = Smoking Cessation within the Context of Lung Cancer Screening.CLINICAL STUDY DESIGNcessation approaches specifically focused on and tailored to underserved populations for whom LCS has been ordered.</s><s xml:id="_xBPwvwu">Our pragmatic RCT among four large U.S. health systems is powered to detect differences in outcomes that are important to patients, clinicians, health systems, and payers.</s><s xml:id="_XAU9t6S">Most importantly, the interventions being tested are highly scalable, thereby facilitating widespread adoption if they are shown to be effective.</s><s xml:id="_t3Sksgh">The results of this trial will help health systems and payers choose smoking cessation interventions to integrate into LCS programs that maximally capitalize on the opportunity LCS presents to promote smoking cessation and reduce healthcare inequities.</s></p></div></figDesc><table><row><cell>Domain</cell><cell>Healthy Lungs</cell><cell>SCALE Trials (22)</cell></row><row><cell>Study design</cell><cell>Pragmatic RCT</cell><cell>Traditional RCTs</cell></row><row><cell></cell><cell></cell><cell>Cluster RCTs</cell></row><row><cell></cell><cell></cell><cell>Sequential multiple-assignment RCTs</cell></row><row><cell></cell><cell></cell><cell>Factorial experimental designs</cell></row><row><cell></cell><cell></cell><cell>(multiphase optimization strategy)</cell></row><row><cell></cell><cell></cell><cell>Modeling of lung cancer screening</cell></row><row><cell></cell><cell></cell><cell>outcomes</cell></row><row><cell>Sites (n)</cell><cell>Four large health systems</cell><cell>1-26 health systems</cell></row><row><cell>Types of lung cancer screening facilities</cell><cell>Academic clinics</cell><cell>Academic clinics</cell></row><row><cell></cell><cell>Community clinics</cell><cell>Community clinics</cell></row><row><cell></cell><cell>Radiology sites</cell><cell>Radiology sites</cell></row><row><cell></cell><cell></cell><cell>Veterans Health Administration clinics</cell></row><row><cell>Sample size</cell><cell>3,200 patients</cell><cell>616-1,650 patients</cell></row><row><cell>Population</cell><cell>Black</cell><cell>Black: 8-37%</cell></row><row><cell></cell><cell>Latinx</cell><cell>Latinx: 0-33%</cell></row><row><cell></cell><cell>Rural</cell><cell></cell></row><row><cell></cell><cell>High school education or less</cell><cell></cell></row><row><cell></cell><cell>Household income ,200% of the federal</cell><cell></cell></row><row><cell></cell><cell>poverty line</cell><cell></cell></row><row><cell>Intervention</cell><cell>Arm 1: AAR</cell><cell>Quitlines</cell></row><row><cell></cell><cell>Arm 2: AAR 1 free or subsidized</cell><cell>Pharmacotherapy</cell></row><row><cell></cell><cell>pharmacotherapy</cell><cell></cell></row><row><cell></cell><cell>Arm 3:</cell><cell>Tailored, individual smoking cessation</cell></row><row><cell></cell><cell>AAR 1 pharmacotherapy 1 financial</cell><cell>counseling</cell></row><row><cell></cell><cell>incentives</cell><cell></cell></row><row><cell></cell><cell>Arm 4:</cell><cell>Development of implementation toolkits</cell></row><row><cell></cell><cell>AAR 1 pharmacotherapy 1 financial</cell><cell>for integrating evidence-based smoking</cell></row><row><cell></cell><cell>incentives 1 episodic future thinking</cell><cell>cessation strategies into lung cancer</cell></row><row><cell></cell><cell></cell><cell>screening</cell></row><row><cell></cell><cell></cell><cell>Digital resources (e.g., web-based</cell></row><row><cell></cell><cell></cell><cell>cessation programs and text message-</cell></row><row><cell></cell><cell></cell><cell>delivered cessation information)</cell></row><row><cell></cell><cell></cell><cell>Gain vs. loss message framing of the</cell></row><row><cell></cell><cell></cell><cell>effects of smoking cessation on health</cell></row><row><cell cols="2">Lung cancer screening eligible vs. completed Both</cell><cell>Both: 1 study</cell></row><row><cell></cell><cell></cell><cell>Eligible: 1 study</cell></row><row><cell></cell><cell></cell><cell>Completed: 6 studies</cell></row><row><cell>Baseline vs. annual screen</cell><cell>Both</cell><cell>Baseline: 1 study</cell></row><row><cell></cell><cell></cell><cell>Both: 7 studies</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_cJMsDPn"><s xml:id="_kVpZMm3">AnnalsATS Volume 19 Number 2 | February 2022</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_j9dvkJg">Acknowledgment:</head><p xml:id="_SvDWkxP"><s xml:id="_9CVpmVN">The authors thank all of their Stakeholder Advisory Committee partners for their contributions and commitment to smoking cessation among underserved patients.</s></p></div>
<div><head xml:id="_7gguJ5r">Stakeholder Advisory</head><p xml:id="_sp6amvw"><s xml:id="_tANwEes">Committee Partners: <rs type="person">Andrea Ferris</rs>, <rs type="person">LUNGevity</rs>; <rs type="person">George Fernandez</rs>, The Latino Connection; <rs type="person">Amanda Holm</rs>, <rs type="affiliation">Tobacco Treatment Service, Center for Health Promotion and Disease Prevention, Henry Ford Health System</rs>; <rs type="person">Sarah Evers-Casey</rs>, Comprehensive Smoking Treatment Program, <rs type="affiliation">University of Pennsylvania</rs>; <rs type="person">Benjamin Broder</rs>, Quality and Clinical Analysis, <rs type="institution">Southern California Permanente Medical Group</rs>; <rs type="person">Curt Hammock</rs>; <rs type="person">Kathy Epps</rs>, The <rs type="institution">Urban League of Philadelphia</rs>; <rs type="person">Karen Yacobucci</rs>, <rs type="person">Henry Ford</rs> <rs type="affiliation">Cancer Institute</rs>; <rs type="person">M. Regina Clanton</rs>; and <rs type="person">Ryan Coffman</rs>, Tobacco Policy and Control Program, <rs type="affiliation">Philadelphia Department of Health</rs>.</s></p></div>
			</div>
			<div type="funding">
<div xml:id="_UPb7qMT"><p xml:id="_XUpVWhm"><s xml:id="_uJWy3Vj">for recusal from review and decisions for authored works.</s></p><p xml:id="_cmeAmBs"><s xml:id="_EbD89tF">A complete list of Stakeholder Advisory Committee Partners may be found before the beginning of the REFERENCES.</s></p><p xml:id="_q6wGtWD"><s xml:id="_DbK9GZC">Supported by the <rs type="funder">Patient-centered Outcomes Research Institute</rs> (<rs type="grantNumber">PCS-2018C1-11326</rs>).</s><s xml:id="_cr3ksjF">R.K. was also supported by the <rs type="funder">National Institutes of Health/National Heart, Lung, and Blood Institute</rs> grant <rs type="grantNumber">K23 HL146894</rs>.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_nNfz7g2">
					<idno type="grant-number">PCS-2018C1-11326</idno>
				</org>
				<org type="funding" xml:id="_R9Fdhwh">
					<idno type="grant-number">K23 HL146894</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_vqKrRd9"><p xml:id="_NKGuaBH"><s xml:id="_z3z7frj">Author disclosures are available with the text of this article at <ref type="url" target="http://www.atsjournals.org">www.atsjournals.org</ref>.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_JhH8wkt">Estimation of cigarette smokingattributable morbidity in the United States</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Rostron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Pechacek</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamainternmed.2014.5219</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QqzqK2q">JAMA Intern Med</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="page" from="1922" to="1928" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rostron BL, Chang CM, Pechacek TF. Estimation of cigarette smoking- attributable morbidity in the United States. JAMA Intern Med 2014;174: 1922-1928.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_9bJwfZD">National Lung Screening Trial Research Team. Reduced lungcancer mortality with low-dose computed tomographic screening</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Aberle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Clapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Fagerstrom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7by99X8">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="395" to="409" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al.; National Lung Screening Trial Research Team. Reduced lung- cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_AXmvcsQ">Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Moyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">S</forename><surname>Services</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Task</forename><surname>Force</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gGmAMpC">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="330" to="338" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:330-338.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_PXAJ9JB">Stakeholder research priorities for smoking cessation interventions within lung cancer screening programs: an official American Thoracic Society research statement</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kathuria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Detterbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Fathi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fennig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Gould</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Jolicoeur</surname></persName>
		</author>
		<idno type="DOI">10.1164/rccm.201709-1858st</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nw6q6Yg">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">196</biblScope>
			<biblScope unit="page" from="1202" to="1212" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kathuria H, Detterbeck FC, Fathi JT, Fennig K, Gould MK, Jolicoeur DG, et al. Stakeholder research priorities for smoking cessation interventions within lung cancer screening programs: an official American Thoracic Society research statement. Am J Respir Crit Care Med 2017;196:1202-1212.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_QurHmCE">Screening for lung cancer: US Preventive Services Task Force recommendation statement</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Krist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Mangione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Barry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cabana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Caughey</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2021.1117</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bhq9jK3">JAMA</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="page" from="962" to="970" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al.; U.S. Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA 2021;325:962-970.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_Dwsxq4q">Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive Services Task Force recommendation</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Humphrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deffebach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pappas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Artis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Mitchell</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-159-6-201309170-00690</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VfhA56B">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="411" to="420" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive Services Task Force recommendation. Ann Intern Med 2013;159:411-420.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_JY92wgU">Annual number of lung cancer deaths potentially avertable by screening in the United States</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
		<idno type="DOI">10.1002/cncr.27813</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VqhBuXW">Cancer</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1381" to="1385" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer 2013; 119:1381-1385.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_Ptp2rj4">Integration of smoking cessation and lung cancer screening</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Steliga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fMnvzaf">Transl Lung Cancer Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="88" to="S94" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Steliga MA, Yang P. Integration of smoking cessation and lung cancer screening. Transl Lung Cancer Res 2019;8:S88-S94.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_SPFEznP">Impact of lung cancer screening results on smoking cessation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Tammemâ¬ Agi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Taylor</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/dju084</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7rwzwNx">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page">84</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tammemâ¬ agi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst 2014;106:dju084.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_QJfaqre">The association between smoking abstinence and mortality in the National Lung Screening Trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Tanner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Kanodra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gebregziabher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Payne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Halbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Warren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8DpYrgF">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">193</biblScope>
			<biblScope unit="page" from="534" to="541" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tanner NT, Kanodra NM, Gebregziabher M, Payne E, Halbert CH, Warren GW, et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am J Respir Crit Care Med 2016;193:534-541.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_Qg2us4b">Association for the Treatment of Tobacco Use and Dependence/ Society for Research on Nicotine and Tobacco Synergy Committee. Pairing smoking-cessation services with lung cancer screening: a clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Fucito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Czabafy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Hendricks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kotsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Toll</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jr7g8Xu">Cancer</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="1150" to="1159" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fucito LM, Czabafy S, Hendricks PS, Kotsen C, Richardson D, Toll BA; Association for the Treatment of Tobacco Use and Dependence/ Society for Research on Nicotine and Tobacco Synergy Committee. Pairing smoking-cessation services with lung cancer screening: a clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Cancer 2016;122:1150-1159.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_xnYBcRE">ATS/ACCP Committee on Low-Dose CT Lung Cancer Screening in Clinical Practice. An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Wiener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Gould</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Arenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Au</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fennig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Lamb</surname></persName>
		</author>
		<idno type="DOI">10.1164/rccm.201508-1671st</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ra5yCej">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="881" to="891" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wiener RS, Gould MK, Arenberg DA, Au DH, Fennig K, Lamb CR, et al.; ATS/ACCP Committee on Low-Dose CT Lung Cancer Screening in Clinical Practice. An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice. Am J Respir Crit Care Med 2015;192:881-891.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_MTkqxeB">A nationwide analysis of US racial/ethnic disparities in smoking behaviors, smoking cessation, and cessation-related factors</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Trinidad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Erez-Stable</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Messer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
		<idno type="DOI">10.2105/ajph.2010.191668</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZPnYxP4">Am J Public Health</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="699" to="706" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Trinidad DR, P erez-Stable EJ, White MM, Emery SL, Messer K. A nationwide analysis of US racial/ethnic disparities in smoking behaviors, smoking cessation, and cessation-related factors. Am J Public Health 2011;101:699-706.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_ThVfjEn">Impact of tobacco control interventions on socioeconomic inequalities in smoking: review of the evidence</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Amos</forename><forename type="middle">A</forename><surname>Clifford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Platt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ahpK8hx">Tob Control</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="89" to="e97" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hill S, Amos A, Clifford D, Platt S. Impact of tobacco control interventions on socioeconomic inequalities in smoking: review of the evidence. Tob Control 2014;23:e89-e97.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_kvzu8ft">Smoking among U.S. Hispanic/Latino adults: the Hispanic community health study/study of Latinos</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Bangdiwala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Barnhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>CastaÃ±eda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Gellman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2014.01.014</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MAGpDVs">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="496" to="506" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaplan RC, Bangdiwala SI, Barnhart JM, CastaÃ±eda SF, Gellman MD, Lee DJ, et al. Smoking among U.S. Hispanic/Latino adults: the Hispanic community health study/study of Latinos. Am J Prev Med 2014;46:496-506.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main" xml:id="_R5eaG5d">Health equity style guide for the COVID-19 response: principles and preferred terms for non-stigmatizing, bias-free language</title>
		<ptr target="https://ehe.jhu.edu/DEI/Health_Equity_Style_Guide_CDC_Reducing_Stigma.pdf" />
		<imprint>
			<date type="published" when="2020-08-11">2020. 2020 Aug 11. 2021 Apr 5</date>
			<publisher>Centers for Disease Control and Prevention</publisher>
			<pubPlace>Atlanta, GA</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Health equity style guide for the COVID-19 response: principles and preferred terms for non-stigmatizing, bias-free language. Atlanta, GA: Centers for Disease Control and Prevention; 2020 [updated 2020 Aug 11; accessed 2021 Apr 5]. Available from: https://ehe.jhu.edu/DEI/ Health_Equity_Style_Guide_CDC_Reducing_Stigma.pdf.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_kT37UhG">Disparities in smoking cessation assistance in US primary care clinics</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Heintzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Jacob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Puro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marino</surname></persName>
		</author>
		<idno type="DOI">10.2105/ajph.2018.304492</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Sfxn9YZ">Am J Public Health</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="1082" to="1090" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bailey SR, Heintzman J, Jacob RL, Puro J, Marino M. Disparities in smoking cessation assistance in US primary care clinics. Am J Public Health 2018;108:1082-1090.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_YN3GGpA">Income disparities in smoking cessation and the diffusion of smoke-free homes among U.S. smokers: results from two longitudinal surveys</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vijayaraghavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Benmarhnia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pierce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kempster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shi</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0208153</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_u9XGTt8">PLoS One</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">e0201467</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vijayaraghavan M, Benmarhnia T, Pierce JP, White MM, Kempster J, Shi Y, et al. Income disparities in smoking cessation and the diffusion of smoke-free homes among U.S. smokers: results from two longitudinal surveys. PLoS One 2018;13:e0201467.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_hcN5mtC">Differences in quit attempts and cigarette smoking abstinence between Whites and African Americans in the United States: literature review and results from the International Tobacco Control US Survey</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kulak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cornelius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Fong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Giovino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_d7dzpjb">Nicotine Tob Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="79" to="S87" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kulak JA, Cornelius ME, Fong GT, Giovino GA. Differences in quit attempts and cigarette smoking abstinence between Whites and African Americans in the United States: literature review and results from the International Tobacco Control US Survey. Nicotine Tob Res 2016;18:S79-S87.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_w5mTPRt">Lung cancer screening as a teachable moment for smoking cessation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zincke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mcguire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gelmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cFTt6Uv">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="125" to="134" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Taylor KL, Cox LS, Zincke N, Mehta L, McGuire C, Gelmann E. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer 2007;56:125-134.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_RtRZrKR">Socioeconomic disparities in quit intentions, quit attempts, and smoking abstinence among smokers in four Western countries: findings from the International Tobacco Control Four Country Survey</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Reid</surname></persName>
			<affiliation>
				<orgName type="collaboration">ITC Collaboration</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hammond</surname></persName>
			<affiliation>
				<orgName type="collaboration">ITC Collaboration</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boudreau</surname></persName>
			<affiliation>
				<orgName type="collaboration">ITC Collaboration</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Fong</surname></persName>
			<affiliation>
				<orgName type="collaboration">ITC Collaboration</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Siahpush</surname></persName>
			<affiliation>
				<orgName type="collaboration">ITC Collaboration</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zaA7vrk">Nicotine Tob Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="20" to="S33" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Reid JL, Hammond D, Boudreau C, Fong GT, Siahpush M; ITC Collaboration. Socioeconomic disparities in quit intentions, quit attempts, and smoking abstinence among smokers in four Western countries: findings from the International Tobacco Control Four Country Survey. Nicotine Tob Res 2010;12:S20-S33.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_wCdPcrF">Lung cancer screening and smoking cessation clinical trials: SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Joseph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Rothman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Almirall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Begnaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Cinciripini</surname></persName>
		</author>
		<idno type="DOI">10.1164/rccm.201705-0909ci</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_znVEA8T">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">197</biblScope>
			<biblScope unit="page" from="172" to="182" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Joseph AM, Rothman AJ, Almirall D, Begnaud A, Chiles C, Cinciripini PM, et al. Lung cancer screening and smoking cessation clinical trials: SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 2018;197: 172-182.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_mJ8eCQD">Smoking behaviors among patients receiving computed tomography for lung cancer screening: systematic review in support of the U.S. Preventive Services Task Force</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Slatore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pappas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Humphrey</surname></persName>
		</author>
		<idno type="DOI">10.1513/annalsats.201312-460oc</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FTpqYx8">Ann Am Thorac Soc</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="619" to="627" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Slatore CG, Baumann C, Pappas M, Humphrey LL. Smoking behaviors among patients receiving computed tomography for lung cancer screening: systematic review in support of the U.S. Preventive Services Task Force. Ann Am Thorac Soc 2014;11:619-627.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_n8ruVh5">Impact of low-dose CT screening on smoking cessation among highrisk participants in the UK Lung Cancer Screening Trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Brain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Lifford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Devaraj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Baldwin</surname></persName>
		</author>
		<idno type="DOI">10.1136/thoraxjnl-2016-209690</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EDg4RYN">Thorax</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="912" to="918" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brain K, Carter B, Lifford KJ, Burke O, Devaraj A, Baldwin DR, et al. Impact of low-dose CT screening on smoking cessation among high- risk participants in the UK Lung Cancer Screening Trial. Thorax 2017; 72:912-918.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_Td4VnNc">Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose</title>
		<author>
			<persName><forename type="first">K</forename><surname>Loudon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zwarenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Donnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Treweek</surname></persName>
		</author>
		<idno type="DOI">10.1186/1745-6215-14-115</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BkBF9nq">Trials</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">115</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Loudon K, Zwarenstein M, Sullivan F, Donnan P, Treweek S. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose. Trials 2013;14:115.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_YKkZM8b">A Pragmatic-Explanatory Continuum Indicator Summary CLINICAL STUDY DESIGN (PRECIS): a tool to help trial designers</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Thorpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zwarenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Treweek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Furberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jBHGWkR">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="464" to="475" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A Pragmatic-Explanatory Continuum Indicator Summary CLINICAL STUDY DESIGN (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62: 464-475.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<ptr target="https://statisticalatlas.com/United-States/Overview" />
		<title level="m" xml:id="_9yHB5GD">Overview of the United States</title>
		<meeting><address><addrLine>Minneapolis, MN</addrLine></address></meeting>
		<imprint>
			<publisher>Cedar Lake Ventures</publisher>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note>updated 2018 Sep 4; accessed 2021 Jun 30</note>
	<note type="raw_reference">Overview of the United States. Minneapolis, MN: Cedar Lake Ventures; 2018 [updated 2018 Sep 4; accessed 2021 Jun 30]. Available from: https://statisticalatlas.com/United-States/Overview.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_pmt5cGR">Randomized trial of four financial-incentive programs for smoking cessation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Halpern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Small</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Saulsgiver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">O</forename><surname>Harhay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Audrain-Mcgovern</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa1414293</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ywPF5YY">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="2108" to="2117" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Halpern SD, French B, Small DS, Saulsgiver K, Harhay MO, Audrain- McGovern J, et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med 2015;372: 2108-2117.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_kkAxpv3">A pragmatic trial of e-cigarettes, incentives, and drugs for smoking cessation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Halpern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">O</forename><surname>Harhay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Saulsgiver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brophy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Troxel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Volpp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_deE8ydc">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="2302" to="2310" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Halpern SD, Harhay MO, Saulsgiver K, Brophy C, Troxel AB, Volpp KG. A pragmatic trial of e-cigarettes, incentives, and drugs for smoking cessation. N Engl J Med 2018;378:2302-2310.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_xMxSVU6">Current cigarette smoking among adults: United States, 2005-2015</title>
		<author>
			<persName><forename type="first">A</forename><surname>Jamal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Neff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Whitmill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Babb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Graffunder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FxYCPsb">MMWR Morb Mortal Wkly Rep</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1205" to="1211" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current cigarette smoking among adults: United States, 2005-2015. MMWR Morb Mortal Wkly Rep 2016;65:1205-1211.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_QCrtUp3">Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: a collaborative modeling study for the US Preventive Services Task Force</title>
		<author>
			<persName><forename type="first">R</forename><surname>Meza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jeon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Toumazis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Haaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bastani</surname></persName>
		</author>
		<idno>No. 20-05266-EF-2</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_GqQKSpk">Cancer Intervention and Surveillance Modeling Network</title>
		<meeting><address><addrLine>Rockville, MD</addrLine></address></meeting>
		<imprint>
			<publisher>Agency for Healthcare Research and Quality</publisher>
			<date type="published" when="2020">2020</date>
		</imprint>
		<respStmt>
			<orgName>CISNET) Lung Cancer Working Group</orgName>
		</respStmt>
	</monogr>
	<note>AHRQ Publication</note>
	<note type="raw_reference">Meza R, Jeon J, Toumazis I, ten Haaf K, Cao P, Bastani M, et al.; Cancer Intervention and Surveillance Modeling Network (CISNET) Lung Cancer Working Group. Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: a collaborative modeling study for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2020. AHRQ Publication No. 20-05266-EF-2.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_C3uRtPX">What to do with a patient who smokes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Schroeder</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.294.4.482</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GNuv5Ay">JAMA</title>
		<imprint>
			<biblScope unit="volume">294</biblScope>
			<biblScope unit="page" from="482" to="487" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schroeder SA. What to do with a patient who smokes. JAMA 2005;294: 482-487.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_UNcKQSS">Varenicline: an a4b2 nicotinic receptor partial agonist for smoking cessation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Coe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Brooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Vetelino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Wirtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2s2EVAr">J Med Chem</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="3474" to="3477" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an a4b2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-3477.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_3gBhaS3">Pharmacotherapy for nicotine dependence</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Henningfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Fant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Buchhalter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Stitzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WQA6Gmm">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page">325</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>quiz</note>
	<note type="raw_reference">Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005;55:281-299; quiz 322-323, 325.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_vscpUkg">The use of bupropion SR in cigarette smoking cessation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wilkes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SXWgr92">Int J Chron Obstruct Pulmon Dis</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="45" to="53" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008;3:45-53.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_BmT7X4s">Initiating pharmacologic treatment in tobacco-dependent adults: an official American Thoracic Society clinical practice guideline</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Leone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Evers-Casey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Evins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Eakin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fathi</surname></persName>
		</author>
		<idno type="DOI">10.1164/rccm.202005-1982st</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_f7pFGGG">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="5" to="e31" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Leone FT, Zhang Y, Evers-Casey S, Evins AE, Eakin MN, Fathi J, et al. Initiating pharmacologic treatment in tobacco-dependent adults: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020;202:e5-e31.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_8qwNSeN">Promoting prevention through the Affordable Care Act</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Sebelius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UDU5hSN">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="1296" to="1299" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Koh HK, Sebelius KG. Promoting prevention through the Affordable Care Act. N Engl J Med 2010;363:1296-1299.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_qvdTz67">Medicaid tobacco cessation: big gaps remain in efforts to get smokers to quit</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Bruen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Steinmetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bysshe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3ueTWpN">Health Aff (Millwood)</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="62" to="70" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ku L, Bruen BK, Steinmetz E, Bysshe T. Medicaid tobacco cessation: big gaps remain in efforts to get smokers to quit. Health Aff (Millwood) 2016;35:62-70.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_Ge42R5M">Tobacco intervention practices of primary care physicians treating lower socioeconomic status patients</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Sheffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Anders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Brackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Steinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Barone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_d8fNnsu">Am J Med Sci</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page" from="388" to="396" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sheffer CE, Anders M, Brackman SL, Steinberg MB, Barone C. Tobacco intervention practices of primary care physicians treating lower socioeconomic status patients. Am J Med Sci 2012;343: 388-396.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_eRY7rc9">Cost-Effectiveness of Four Financial-Incentive Programs for Smoking Cessation</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Volpp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Kwong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Cosgriff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">O</forename><surname>Harhay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PjuyuA9">Ann Am Thorac Soc</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1997" to="2006" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Russell LB, Volpp KG, Kwong PL, Cosgriff BS, Harhay MO, Zhu J, et al. Cost-Effectiveness of Four Financial-Incentive Programs for Smoking Cessation. Ann Am Thorac Soc 2021;18:1997-2006.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_QCCvRt5">Influence of an alternative reinforcer on human cocaine self-administration</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Bickel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_C8tP5Xj">Life Sci</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="179" to="187" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Higgins ST, Bickel WK, Hughes JR. Influence of an alternative reinforcer on human cocaine self-administration. Life Sci 1994;55: 179-187.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_TubfGmM">Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude</title>
		<author>
			<persName><forename type="first">K</forename><surname>Silverman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Chutuape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Bigelow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Stitzer</surname></persName>
		</author>
		<idno type="DOI">10.1007/s002130051098</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Dkfdpab">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="128" to="138" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Silverman K, Chutuape MA, Bigelow GE, Stitzer ML. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology (Berl) 1999;146:128-138.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_BP8zknR">Does delay discounting play an etiological role in smoking or is it a consequence of smoking?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Audrain-Mcgovern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cuevas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rodgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Wileyto</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.drugalcdep.2008.12.019</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tRWDxCh">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="99" to="106" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Audrain-McGovern J, Rodriguez D, Epstein LH, Cuevas J, Rodgers K, Wileyto EP. Does delay discounting play an etiological role in smoking or is it a consequence of smoking? Drug Alcohol Depend 2009;103: 99-106.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_BsuGusP">Thinking forward: futureoriented thinking among patients with tobacco-associated thoracic diseases and their surrogates</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pflug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Madden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Halpern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ykcA4jM">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">193</biblScope>
			<biblScope unit="page" from="321" to="329" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hart JL, Pflug E, Madden V, Halpern SD. Thinking forward: future- oriented thinking among patients with tobacco-associated thoracic diseases and their surrogates. Am J Respir Crit Care Med 2016;193: 321-329.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_5mr84YR">Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Bickel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Odum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Madden</surname></persName>
		</author>
		<idno type="DOI">10.1007/pl00005490</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_h6j72JR">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="447" to="454" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bickel WK, Odum AL, Madden GJ. Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology (Berl) 1999;146:447-454.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_9q5STSk">Prospection: experiencing the future</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gYqc2xT">Science</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page" from="1351" to="1354" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gilbert DT, Wilson TD. Prospection: experiencing the future. Science 2007;317:1351-1354.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_gfXPUsc">Attitudes and perceptions about smoking cessation in the context of lung cancer screening</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Zeliadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Heffner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sayre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Simons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Williams</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamainternmed.2015.3558</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZUAg7CN">JAMA Intern Med</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="page" from="1530" to="1537" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zeliadt SB, Heffner JL, Sayre G, Klein DE, Simons C, Williams J, et al. Attitudes and perceptions about smoking cessation in the context of lung cancer screening. JAMA Intern Med 2015;175: 1530-1537.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_z9AaXXy">Living in the moment: effects of time perspective and emotional valence of episodic thinking on delay discounting</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
		<idno type="DOI">10.1037/a0035705</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FfS38Yk">Behav Neurosci</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="12" to="19" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lin H, Epstein LH. Living in the moment: effects of time perspective and emotional valence of episodic thinking on delay discounting. Behav Neurosci 2014;128:12-19.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_yZ7YTH7">Setting a goal could help you control: comparing the effect of health goal versus general episodic future thinking on health behaviors among cigarette smokers and obese individuals</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Athamneh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Mellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Gatchalian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JWxVVwp">Exp Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="59" to="72" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Athamneh LN, Stein MD, Lin EH, Stein JS, Mellis AM, Gatchalian KM, et al. Setting a goal could help you control: comparing the effect of health goal versus general episodic future thinking on health behaviors among cigarette smokers and obese individuals. Exp Clin Psychopharmacol 2021;29:59-72.</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_zyXm9NU">Episodic future thinking reduces delay discounting and cigarette demand: an investigation of the good-subject effect</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Tegge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Bickel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YUrJ2kd">J Behav Med</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="269" to="276" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stein JS, Tegge AN, Turner JK, Bickel WK. Episodic future thinking reduces delay discounting and cigarette demand: an investigation of the good-subject effect. J Behav Med 2018;41:269-276.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_t9CWp5D">Acute and extended exposure to episodic future thinking in a treatment seeking addiction sample: a pilot study</title>
		<author>
			<persName><forename type="first">H</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Amlung</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jsat.2020.108046</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BMWhMbe">J Subst Abuse Treat</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page">108046</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Patel H, Amlung M. Acute and extended exposure to episodic future thinking in a treatment seeking addiction sample: a pilot study. J Subst Abuse Treat 2020;116:108046.</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_xqzKNUc">Do process simulations during episodic future thinking enhance the reduction of delay discounting for middle income participants and those living in poverty?</title>
		<author>
			<persName><forename type="first">S</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">O</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Koroschetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kilanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Otminski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Bickel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HEVctMu">J Behav Decis Making</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="231" to="240" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Donnell S, Daniel TO, Koroschetz J, Kilanowski C, Otminski A, Bickel WK, et al. Do process simulations during episodic future thinking enhance the reduction of delay discounting for middle income participants and those living in poverty? J Behav Decis Making 2019; 32:231-240.</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_b7vFMmg">Misdirections in informed consent: impediments to health care innovation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Asch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Ziolek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Mehta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KeCFn7s">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="1412" to="1414" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Asch DA, Ziolek TA, Mehta SJ. Misdirections in informed consent: impediments to health care innovation. N Engl J Med 2017;377: 1412-1414.</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_NJYqJkP">An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Faden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Kass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pronovost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tunis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Beauchamp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kKdHgkm">Hastings Cent Rep</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="16" to="S27" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Faden RR, Kass NE, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. Hastings Cent Rep 2013;43:S16-S27.</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_YANgz4k">Methods for the Watch the Spot Trial: a pragmatic trial of more-versus less-intensive strategies for active surveillance of small pulmonary nodules</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Gould</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Smith-Bindman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Barjaktarevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Creekmur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jFcwp53">Ann Am Thorac Soc</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1567" to="1576" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gould MK, Smith-Bindman R, Kelly K, Altman DE, Barjaktarevic I, Creekmur B, et al. Methods for the Watch the Spot Trial: a pragmatic trial of more-versus less-intensive strategies for active surveillance of small pulmonary nodules. Ann Am Thorac Soc 2019;16:1567-1576.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_GqVfNFC">Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Courtright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Halpern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Joffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ellenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Karlawish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Madden</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-017-2217-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DNpyC6D">Trials</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">474</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Courtright KR, Halpern SD, Joffe S, Ellenberg SS, Karlawish J, Madden V, et al. Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach. Trials 2017;18:474.</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_MCjHtzu">Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kraybill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Dember</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Joffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Karlawish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ellenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Madden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hTwRvJR">AJOB Empir Bioeth</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="106" to="115" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kraybill A, Dember LM, Joffe S, Karlawish J, Ellenberg SS, Madden V, et al. Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. AJOB Empir Bioeth 2016;7: 106-115.</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_RCbESgQ">What should be disclosed to research participants?</title>
		<author>
			<persName><forename type="first">D</forename><surname>Wendler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eDhbjAU">Am J Bioeth</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="3" to="8" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wendler D. What should be disclosed to research participants? Am J Bioeth 2013;13:3-8.</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_STNCwHG">Outcome criteria in smoking cessation trials: proposal for a common standard</title>
		<author>
			<persName><forename type="first">R</forename><surname>West</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hajek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Stead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stapleton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_er2PmQU">Addiction</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="299" to="303" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100: 299-303.</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_YyS6Kq4">Measures of abstinence in clinical trials: issues and recommendations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Keely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Niaura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Ossip-Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Richmond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Swan</surname></persName>
		</author>
		<idno type="DOI">10.1080/1462220031000070552</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vvWHHvk">Nicotine Tob Res</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="13" to="25" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003;5:13-25.</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_fGEKhJR">The contemplation ladder: validation of a measure of readiness to consider smoking cessation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Biener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Abrams</surname></persName>
		</author>
		<idno type="DOI">10.1037//0278-6133.10.5.360</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SzUgWJf">Health Psychol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="360" to="365" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Biener L, Abrams DB. The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol 1991;10: 360-365.</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_7UMdYjD">Effects of smoking cues and argument strength of antismoking advertisements on former smokers&apos; self-efficacy, attitude, and intention to refrain from smoking</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Cappella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Strasser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xySeV9r">Nicotine Tob Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="527" to="533" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lee S, Cappella JN, Lerman C, Strasser AA. Effects of smoking cues and argument strength of antismoking advertisements on former smokers&apos; self-efficacy, attitude, and intention to refrain from smoking. Nicotine Tob Res 2013;15:527-533.</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_93ZqQxB">Development and validation of a 21-item challenges to stopping smoking (CSS-21) scale</title>
		<author>
			<persName><forename type="first">D</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Mackinnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bonevski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Abramson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Poole</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2016-011265</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7Dsk9h9">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">11265</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thomas D, Mackinnon AJ, Bonevski B, Abramson MJ, Taylor S, Poole SG, et al. Development and validation of a 21-item challenges to stopping smoking (CSS-21) scale. BMJ Open 2016;6:e011265.</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_JYmyqM8">A 5-trial adjusting delay discounting task: accurate discount rates in less than one minute</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Koffarnus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Bickel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8QFbdsS">Exp Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="222" to="228" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Koffarnus MN, Bickel WK. A 5-trial adjusting delay discounting task: accurate discount rates in less than one minute. Exp Clin Psychopharmacol 2014;22:222-228.</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_HqdADE4">Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Herdman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gudex</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Janssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kind</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Parkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cg32eF6">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1727" to="1736" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-1736.</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_TsFS87d">A multiple comparison procedure for three-and four-armed controlled clinical trials</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Proschan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HWB3rQH">Stat Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="787" to="798" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Proschan MA. A multiple comparison procedure for three-and four-armed controlled clinical trials. Stat Med 1999;18:787-798.</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_HPAVXvd">Do covariates change the estimand?</title>
		<author>
			<persName><forename type="first">T</forename><surname>Permutt</surname></persName>
		</author>
		<idno type="DOI">10.1080/19466315.2019.1647874</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wdgeYTd">Stat Biopharm Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="45" to="53" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Permutt T. Do covariates change the estimand? Stat Biopharm Res 2020;12:45-53.</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_vhnBZVR">The Fagerstrâ¬ om test for nicotine dependence: a revision of the Fagerstrâ¬ om Tolerance Questionnaire</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Heatherton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Kozlowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Frecker</surname></persName>
		</author>
		<author>
			<persName><surname>Fagerstrâ¬</surname></persName>
		</author>
		<author>
			<persName><surname>Ko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9rvhnXC">Br J Addict</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="1119" to="1127" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrâ¬ om KO. The Fagerstrâ¬ om test for nicotine dependence: a revision of the Fagerstrâ¬ om Tolerance Questionnaire. Br J Addict 1991;86:1119-1127.</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main" xml:id="_E7juGGS">S moking cessation in the ITALUNG Lung Cancer Screening: what does &quot;teachable moment&quot; mean?</title>
		<author>
			<persName><forename type="first">F</forename><surname>Pistelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Aquilini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Falaschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Puliti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ocello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lopes</forename><surname>Pegna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kYtFjUF">Nicotine Tob Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1484" to="1491" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pistelli F, Aquilini F, Falaschi F, Puliti D, Ocello C, Lopes Pegna A, et al. S moking cessation in the ITALUNG Lung Cancer Screening: what does &quot;teachable moment&quot; mean? Nicotine Tob Res 2020;22:1484-1491.</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_T2DqEcc">Two-stage instrumental variable methods for estimating the causal odds ratio: analysis of bias</title>
		<author>
			<persName><forename type="first">B</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Small</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Have</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_R7vMSKg">Stat Med</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1809" to="1824" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cai B, Small DS, Have TR. Two-stage instrumental variable methods for estimating the causal odds ratio: analysis of bias. Stat Med 2011;30: 1809-1824.</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_RAHZQ8B">Econometrics in outcomes research: the use of instrumental variables</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Newhouse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mcclellan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_C2a8xzY">Annu Rev Public Health</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="17" to="34" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998;19:17-34.</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_3zeh9N7">Identification of causal effects using instrumental variables</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Angrist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Imbens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rubin</forename><surname>Db</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8SPcV9J">J Am Stat Assoc</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="444" to="455" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996;91:444-455.</note>
</biblStruct>

<biblStruct xml:id="b72">
	<monogr>
		<ptr target="https://www.equator-network.org/" />
		<title level="m" xml:id="_8kjfx6p">Enhancing the quality and transparency of health research</title>
		<meeting><address><addrLine>Oxford, UK</addrLine></address></meeting>
		<imprint>
			<publisher>University of Oxford</publisher>
			<date type="published" when="2020-10-23">2020. 2020 Oct 23</date>
		</imprint>
		<respStmt>
			<orgName>EQUATOR Network</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">EQUATOR Network. Enhancing the quality and transparency of health research. Oxford, UK: University of Oxford; 2020 [accessed 2020 Oct 23]. Available from: https://www.equator-network.org/.</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main" xml:id="_7QvemT9">Waivers and alterations of research informed consent during the COVID-19 pandemic</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Largent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Halpern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fernandez</forename><surname>Lynch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ukByQKZ">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="page" from="415" to="416" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Largent EA, Halpern SD, Fernandez Lynch H. Waivers and alterations of research informed consent during the COVID-19 pandemic. Ann Intern Med 2021;174:415-416.</note>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<ptr target="https://www.pewresearch.org/internet/fact-sheet/mobile/.76" />
		<title level="m" xml:id="_gTwYJHq">Mobile fact sheet</title>
		<meeting><address><addrLine>Washington, DC</addrLine></address></meeting>
		<imprint>
			<publisher>Pew Research Center</publisher>
			<date type="published" when="2021-06-01">2021. 2021 Jun 1</date>
		</imprint>
	</monogr>
	<note>Detailed languages spoken at home and ability to speak English for the population 5 years and over: 2009-2013</note>
	<note type="raw_reference">Mobile fact sheet. Washington, DC: Pew Research Center; 2021 [accessed 2021 Jun 1]. Available from: https://www.pewresearch.org/ internet/fact-sheet/mobile/. 76 Detailed languages spoken at home and ability to speak English for the population 5 years and over: 2009-2013.</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Suitland</surname></persName>
		</author>
		<ptr target="https://www.census.gov/data/tables/2013/demo/2009-2013-lang-tables.html" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_m6SVRX4">U.S. Census Bureau</title>
		<imprint>
			<date type="published" when="2015">2015. 2021 Feb 22</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Suitland, MD: U.S. Census Bureau; 2015 [accessed 2021 Feb 22]. Available from: https://www.census.gov/data/tables/2013/demo/2009-2013-lang- tables.html.</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main" xml:id="_XTKxdJV">Trends in lung cancer screening in the United States, 2016-2017</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Okereke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Goodwin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RyZS2Gj">J Thorac Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="873" to="881" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Okereke IC, Nishi S, Zhou J, Goodwin JS. Trends in lung cancer screening in the United States, 2016-2017. J Thorac Dis 2019;11:873-881.</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main" xml:id="_5DywYKj">Applying the transtheoretical model to a representative sample of smokers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Fava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Velicer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Prochaska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8F3Xdu5">Addict Behav</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="189" to="203" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fava JL, Velicer WF, Prochaska JO. Applying the transtheoretical model to a representative sample of smokers. Addict Behav 1995;20:189-203.</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main" xml:id="_v2GapyP">News about genetics and smoking: priming, family smoking history, and news story believability on inferences of genetic susceptibility to tobacco addiction</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Cappella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Romantan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Baruh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mbG7Uhe">Communic Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="478" to="502" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cappella JN, Lerman C, Romantan A, Baruh L. News about genetics and smoking: priming, family smoking history, and news story believability on inferences of genetic susceptibility to tobacco addiction. Communic Res 2005;32:478-502.</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main" xml:id="_SwaJAKm">EuroQol: a new facility for the measurement of health-related quality of life</title>
		<author>
			<persName><forename type="first">Euroqol</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_n5gDaQC">Health Policy</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="199" to="208" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note type="raw_reference">EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16: 199-208.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
